Eli Lilly sees 2026 profit above estimates on weight‑loss drug demand

Eli Lilly forecast 2026 profit above Wall Street estimates on Wednesday, as it expects strong demand for its blockbuster weight-loss and diabetes drugs, Zepbound and Mounjaro, to offset pricing pressures in the U.S., its largest market. ...